Verified by Psychology Today

Adi Zuloff-Shani Ph.D.

About

Adi Zuloff-Shani, Ph.D., is the CEO of Clearmind Medicine [NASDAQ: CMND], a biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder as well as other pressing health challenges and addictions. The mentee of Raphael Mechoulam ("the godfather of cannabis research"), Dr. Zuloff-Shani works across scientific disciplines to bring new therapeutics through regulatory processes in the U.S., E.U., and Israel.

Dr. Zuloff-Shani holds a Bachelor of Science degree in Biology, a Master of Science degree in Immunology, and a Doctorate of Science degree in Immunology, all from Bar Ilan University. She is Chairman of Orsus Therapeutics Ltd. and serves on the advisory boards of Save Foods, Inc. [NASDAQ: SVFD]. Her executive experience in Research & Development in the biotech industry is combined with clinical work and knowledge of cell biology, innate immunity, tissue healing, and regeneration.

As CTO of SciSparc [NASDAQ: SPRC]—formerly Therapix Biosciences Ltd—Dr. Zuloff-Shani successfully brought products from bench to market for health challenges such as Tourette’s and obstructive sleep apnea and for CNS-related indications such as agitation in Alzheimer's, autism sectrum disorder, and pain. Prior to joining SciSparc, she served as Vice President of Development at Macrocure [NASDAQ: MCUR],

Recent Posts
From War Zones to Healing Minds
Psychedelic-based therapies for PTSD offer hope for breakthroughs in therapy and peace-building, even in conflict zones like the Middle East.
Ready or Not, Psychedelic-Assisted Therapy Is Happening

Is the world ready for psychedelic-assisted therapy? How do we prepare ourselves and ensure that we reduce the possibility of harm?

Is the world ready for psychedelic-assisted therapy? How do we prepare ourselves and ensure that we reduce the possibility of harm?

Navigating the Long Road to FDA Approval

The CEO of a psychedelic biotech company reflects on the challenges and opportunities in FDA regulation for new health solutions.

The CEO of a psychedelic biotech company reflects on the challenges and opportunities in FDA regulation for new health solutions.

Celebrities Are Speaking Out on Psychedelics

Access to the therapeutic potential of psychedelics should be available for all people, not just the wealthy and privileged.

Access to the therapeutic potential of psychedelics should be available for all people, not just the wealthy and privileged.

To Fight Alcohol Addiction, We Need More Than a Dry January

Overcoming alcohol addiction is a daunting challenge. Psychedelics could be the game-changing solution we've been looking for.

Overcoming alcohol addiction is a daunting challenge. Psychedelics could be the game-changing solution we've been looking for.